Evidence map›Paper›PMID 28448787›Full record

ArticleCancer biology & therapy2017

Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer.

An-Quan Shang, Jian Wu, Feng Bi, Yu-Jie Zhang, Lei-Rong Xu, Ling-Ling Li, Fei-Fei Chen, Wei-Wei Wang, Jian-Jun Zhu, You-Yi Liu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Affibody-based molecular probeOpen medicine (Warsaw, Poland) · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

An-Quan Shanga Clinical Medicine School , Ningxia Medical University , Yinchuan , P.R. China.
Jian Wuc Department of Oncology , The Sixth People's Hospital of Yancheng City , Yancheng , P.R. China.
Feng Bid Department of Obstetrics and Gynecology , The Sixth People's Hospital of Yancheng City , Yancheng , P.R. China.
Yu-Jie Zhanga Clinical Medicine School , Ningxia Medical University , Yinchuan , P.R. China.
Lei-Rong Xuc Department of Oncology , The Sixth People's Hospital of Yancheng City , Yancheng , P.R. China.
Ling-Ling Lic Department of Oncology , The Sixth People's Hospital of Yancheng City , Yancheng , P.R. China.
Fei-Fei Chenc Department of Oncology , The Sixth People's Hospital of Yancheng City , Yancheng , P.R. China.
Wei-Wei Wange Department of Pathology , The First People's Hospital of Yancheng City , Yancheng , P.R. China.
Jian-Jun Zhuc Department of Oncology , The Sixth People's Hospital of Yancheng City , Yancheng , P.R. China.
You-Yi Liug Department of Gynecology and Obstetrics , Fifth Hospital in Wuhan , Wuhan , Hubei Province , P.R. China.
Yancheng Third People's Hospital · CNNingxia Medical University · CNWuhan University · CNYancheng First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe study aims to explore the relationship between expressions of HER2 and JAK/STAT3-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer (OC).

methodsA total of 136 OC patients were collected. Immunohistochemistry was applied to measure the expressions of STAT3, p-STAT3, SOCS3, HER2 and p-HER2 in the tumor tissues and adjacent normal tissues. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the mRNA expressions of HER2, SOCS3 and STAT3 and western blotting was applied for protein expressions of HER2, p-HER2, SOCS3, STAT3 and p-STAT3 in the tumor tissues and adjacent normal tissues. Flow cytometry was used for the cell apoptosis in the blank, afatinib (A), ruxolitinib (R) and afatinib + ruxolitinib (A + R) groups. Follow-up was performed to explore relationship of HER2, SOCS3, and STAT3 expressions with survival time of OC patients.

resultsHER2, p-HER2, STAT3, and p-STAT3 expressions were higher while SOCS3 expression was lower in the tumor tissues. The positive expressions of STAT3, HER2, p-HER2 and p-STAT3 were lower while the positive expression of SOCS3 was higher in the adjacent normal tissues. The expressions of HER2, SOCS3, and p-STAT3 were associated with clinical stage and lymph node metastasis (LNM), and STAT3 expression has correlation with histological grade and LNM. The mRNA and protein expressions of HER2, STAT3 and p-STAT3 in the tumor tissues were higher than those in the adjacent normal tissues, but SOCS3 expression was significantly decreased. The positive expressions of HER2, p-HER2 and STAT3, the negative expression of SOCS3 and pathological stages were important risk factors for the prognosis of patients with OC.

conclusionOur study showed that the expressions of HER2, STAT3, and SOCS3 are associated with the progression of OC, and higher expressions of HER2 and STAT3 and lower expression of SOCS3 predict poor prognosis of OC.

Indexed as

AdultAgedDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesFemaleGene Expression Regulation, NeoplasticHumansJanus KinasesLymphatic MetastasisMiddle AgedOvarian NeoplasmsPrognosisRisk FactorsSignal TransductionSTAT3 Transcription FactorSuppressor of Cytokine Signaling 3 ProteinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesJanus KinasesSOCS3 protein, humanSTAT3 protein, humanSTAT3 Transcription FactorSuppressor of Cytokine Signaling 3 ProteinClinicopathological featureshuman epidermal growth factor receptor 2ovarian cancerprognosissignaling pathwaysignal transducer and activator of transcription 3suppressors of cytokine signaling 3

Identifiers

PMID28448787
PMCPMC5499756
OpenAlexW2608872586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.